H.C. Wainwright lowered the firm’s price target on Genfit (GNFT) to $7 from $9 and keeps a Buy rating on the shares. The company last week announced the discontinuation of VS-01 in acute on chronic liver failure following a case of peritonitis in the UNVEIL-IT study, the analyst tells investors in a research note. The firm updated Genfit’s model for the discontinuation and the company’s half year earnings report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNFT:
- Genfit’s 2025 Mid-Year Financial and Strategic Update
- GENFIT S.A. Releases Half-Year Financial Report for 2025
- GENFIT’s Strategic Shift and Financial Update for H1 2025
- GENFIT Discontinues VS-01 Program in ACLF to Focus on UCD
- Genfit SA: Strategic Positioning and Undervalued Potential in Biotechnology Sector